

## ARTÍCULOS DE MAYOR FACTOR DE IMPACTO NOVIEMBRE Y DICIEMBRE 2014

Saura, C; **García-Saenz, JA**; Xu, BH; Harb, W; Morooso, R; Pluard, T; Cortes, J; Kiger, C; Germa, C; Wang, KM; Martin, M; Baselga, J; Kim, SB. *Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer*. JOURNAL OF CLINICAL ONCOLOGY 2014; 32(32):3626-33. doi: 10.1200/JCO.2014.56.3809; FACTOR DE IMPACTO: 17.960

Enlace: <http://jco.ascopubs.org/content/32/32/3626.full.pdf+html>

### Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Cristina Saura, Jose A. Garcia-Saenz, Binghe Xu, Wael Harb, Rebecca Morooso, Timothy Pluard, Javier Cortés, Corinne Kiger, Caroline Germa, Kongming Wang, Miguel Martín, José Baselga, and Sung-Bae Kim

#### A B S T R A C T

##### Purpose

Neratinib is a potent irreversible pan-tyrosine kinase inhibitor with antitumor activity and acceptable tolerability in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A multinational, open-label, phase I/II trial was conducted to determine the maximum-tolerated dose (MTD) of neratinib plus capecitabine in patients with solid tumors (part one) and to evaluate the safety and efficacy of neratinib plus capecitabine in patients with HER2-positive metastatic breast cancer (part two).

Spelman, Tim; Gray, Orla; Trojano, Maria; Petersen, Thor; Izquierdo, Guillermo; Lugaresi, Alessandra; Hupperts, Raymond; Bergamaschi, Roberto; Duquette, Pierre; Grammond, Pierre; Giuliani, Giorgio; Boz, Cavit; Verheul, Freek; **Oreja-Guevara, Celia**; Barnett, Michael; Grand'Maison, Francois; Rio, Maria Edite; Lechner-Scott, Jeannette; Van Pesch, Vincent; Fernandez Bolanos, Ricardo; Flechter, Shlomo; Den Braber-Moerland, Leontien; Iuliano, Gerardo; Amato, Maria Pia; Slee, Mark; Cristiano, Edgardo; Laura Saladino, Maria; Paine, Mark; Vella, Norbert; Kasa, Krisztian; Deri, Norma; Herbert, Joseph; Moore, Fraser; Petkovska-Boskova, Tatjana; Alroughani, Raed; Savino, Aldo; Shaw, Cameron; Vucic, Steve; Santiago, Vetere; Alejandra Bacile, Elizabeth; Skromne, Eli; Poehlau, Dieter; Antonio Cabrera-Gomez, Jose; Lucas, Robyn; Butzkueven, Helmut. *Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent*. ANNALS OF NEUROLOGY 2014; **Dec;76(6):880-90**. doi: 10.1002/ana.24287. FACTOR DE IMPACTO: 11.910

Enlace:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=Seasonal+Variation+of+Relapse+Rate+in+Multiple+Sclerosis+is+Latitude+Dependent>

Ann Neurol. 2014 Dec;76(6):880-90. doi: 10.1002/ana.24287. Epub 2014 Oct 20.

#### Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

Spelman T<sup>1</sup>, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H.

#### Author information

##### Abstract

**OBJECTIVE:** Previous studies assessing seasonal variation of relapse onset in multiple sclerosis have had conflicting results. Small relapse numbers, differing diagnostic criteria, and single region studies limit the generalizability of prior results. The aim of this study was to determine whether there is a temporal variation in onset of relapses in both hemispheres and to determine whether seasonal peak relapse probability varies with latitude.